Last reviewed · How we verify
Canakinumab Injection (canakinumab-injection)
Canakinumab Injection is a monoclonal antibody that targets and neutralizes interleukin-1 beta (IL-1β) to treat inflammatory conditions.
Canakinumab Injection, developed by Pfizer, holds a significant market position with annual revenues of $372M and is indicated for five inflammatory conditions. Its competitive advantage lies in its specific mechanism as a monoclonal antibody targeting IL-1β, distinguishing it from alternatives like Colchicine, Indomethacin, Naproxen, Ibuprofen, and Methylprednisolone, which are primarily used for gout treatment. A key risk is the requirement for a PD-L1 companion diagnostic for several of its indications, which may limit its accessibility and broaden its application challenges. Despite no ongoing clinical trials, the established revenue and multiple approved indications suggest a stable pipeline outlook.
At a glance
| Generic name | canakinumab-injection |
|---|---|
| Sponsor | Pfizer |
| Drug class | Monoclonal Antibody |
| Target | IL-1β |
| Modality | Monoclonal antibody |
| Phase | FDA-approved |
| Annual revenue | 372 |
Mechanism of action
Canakinumab Injection is a monoclonal antibody that targets and neutralizes interleukin-1 beta (IL-1β), a key cytokine involved in the inflammatory process. This targeted approach provides a more precise and effective treatment approach compared to traditional anti-inflammatory medications. By neutralizing IL-1β, Canakinumab Injection reduces inflammation and prevents the progression of various inflammatory conditions.
Approved indications
- Prophylaxis of gouty arthritis attacks in adults
- Prophylaxis of gouty arthritis attacks in pediatric patients 2 years of age and older
- Treatment of cryopyrin-associated periodic syndromes (CAPS) in adults and children 4 months of age and older
- Treatment of systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older
- Treatment of Familial Mediterranean Fever (FMF) in adults and children 4 months of age and older
Common side effects
- General AE
- Acute Kidney Injury
- Anemia
- Acute respiratory distress syndrome
- Diarrhoea
- Bronchitis
- Conjunctivitis
- Gastroenteritis
- Drug eruption
- Hypertension
- Arrhythmia
- Elevated Ferritin
Drug interactions
- Abatacept
- Anakinra
- Bacillus Calmette-Guérin (BCG) vaccine
- Live vaccines
- Other vaccines
- Rituximab
- Tofacitinib
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Canakinumab Injection CI brief — competitive landscape report
- Canakinumab Injection updates RSS · CI watch RSS
- Pfizer portfolio CI